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Abstract
Background: Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with
HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised
controlled trial comparing 6- to 12-months of trastuzumab. In this trial there will be a trade-off between a possible small
decrease in disease-free survival (DFS) with 6-months and reduced cardiotoxicity and cost.
Methods: A structured questionnaire asked clinicians who had recruited patients into the Persephone trial about their
prior beliefs with regards to the clinical effectiveness of trastuzumab and cardiotoxicity profile, in the comparison of
6- and 12-month durations.
Results: Fifty-one clinicians from 40 of the 152 Persephone sites completed the questionnaire. 30/50 responders (60%)
believed that 6-months trastuzumab would give the same 4-year DFS rate as 12-months trastuzumab, with 21/50 (42%)
holding this belief across all breast cancer subsets. In addition, 46/49 responders (94%) reported expecting to change
their clinical practice to 6-months, with their prior beliefs (most commonly 85% 4-year DFS rate with 6-months) being
greater than their lowest acceptable rate (most commonly 83% 4-year DFS rate with 6-months). Low levels of
cardiotoxicity were expected with both 6 and 12-months trastuzumab, with the majority expecting lower levels
with 6-months. With increasing hypothesised differences of cardiotoxicity rates between the two durations, significantly
lower levels of 4-year DFS with 6-months trastuzumab were deemed acceptable (p < 0.0001).
Conclusion: Most responders believe that 6-months trastuzumab is adequate, both overall and within each subset
of breast cancer, and plan to change their clinical practice if the Persephone results support their prior belief. An
individual patient meta-analysis of the duration trials would give greater precision to estimates of the differences
in efficacy and toxicity, and adequate statistical power to establish a 2% level of non-inferiority for 6-months adjuvant
trastuzumab.
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Background
Adjuvant trastuzumab treatment is proven to improve
disease-free survival (DFS) and overall survival (OS) in
HER2 positive early breast cancers. The results of the
US and international adjuvant trastuzumab trials pub-
lished in 2005–2011 [1–4] established 12 months of ad-
juvant trastuzumab as the clinical standard. In addition
the HERA trial has recently confirmed that 24 months
treatment does not further improve DFS and OS but
does increase cardiac toxicity [5]. Investigation is still
ongoing into shorter durations of adjuvant trastuzumab
that could potentially provide an optimal balance be-
tween efficacy, cost and cardiac / other toxicity. Trials of
trastuzumab duration comparing shorter durations to
12 months include PHARE [6], the HORG trial [7] and
Persephone, which all compare 6 versus 12 months. In
addition the Short-HER (NCT00629278) and SOLD
(NCT00593697) trials have investigated 9 weeks versus
12 months duration. However, the PHARE trial, reported
in 2013 [6], the HORG trial, reported in 2015 [7] and
the Short-HER trial presented in 2017 [8], all failed to
prove non-inferiority. The Persephone trial, completed
target recruitment of 4000 patients in July 2015 and the
primary endpoint results of DFS non-inferiority in an
event-driven analysis are expected by June 2018.
The type, severity and length of increased risk of cardi-
otoxicity with trastuzumab treatment is also still being
investigated with regard to the different treatment dura-
tions alongside various chemotherapy regimens. A num-
ber of trials have reported results by different categories:
New York Heart Association Functional Classifications;
absolute or relative declines in left ventricular ejection
fraction (LVEF) percentages; signs and / or symptoms of
congestive heart failure (CHF); new use or alteration of
cardiac medication; and finally prevalence of cardiac
deaths attributable to trastuzumab. The cardiac data
from the HERA trial [5, 9–12] and the US studies [13,
14] show a clear relationship between the duration of
trastuzumab exposure and incidence of cardiac dysfunc-
tion. This was confirmed both in PHARE [15] and the
cardiac analysis of the first 2500 patients in the Perseph-
one Trial [16].
There are plans for an international trastuzumab dur-
ation meta-analysis which will aim to further investigate
the benefits of the different durations of trastuzumab
treatment in breast cancer patients as a whole as well as
in specific pre-specified subsets. The Persephone, PHARE
and Short-HER Trials Groups have been in discussion
with regards to this future meta-analysis, and a survey was
proposed to establish clinicians’ prior beliefs with regard
to the level of non-inferiority deemed acceptable in order
to change their current prescribing practice.
To address this issue, a questionnaire was designed to
ask clinicians who had recruited patients into Persephone
about their current clinical beliefs of the effectiveness and
cardiotoxicity profile of 6 and 12 months adjuvant trastu-
zumab treatment in the HER2 breast cancer setting. The
aim was to inform not only the potential practice-
changing impact of the Persephone trial, but also on the
most appropriate non-inferiority limits to define for a fu-
ture meta-analysis of the ‘12 month trastuzumab versus
less’ trials for further investigation into pre-specified sub-
sets of patients.
Methods
Between May 2015 and July 2016, members of the Per-
sephone trial team developed a structured questionnaire
(see Additional file 1) to ask clinicians about their prior
beliefs of the effectiveness and cardiotoxicity profile of ad-
juvant trastuzumab treatment in the HER2 positive early
breast cancer setting, specifically with regards to the com-
parison between 12 month and 6 month duration.
The 20-point questionnaire comprised questions relat-
ing to five areas: (i) levels of DFS with the two treatment
durations; (ii) the relative efficacy of 6 and 12 months
trastuzumab in various specified subsets of patients; (iii)
rates of cardiotoxicity with 6 and 12 months trastuzu-
mab; (iv) acceptable trade-offs between decreases in car-
diotoxicity rates and decreases in DFS; (v) any aspect of
the comparison between various durations of trastuzu-
mab treatment. Responders were allowed to remain an-
onymous, although all did include their names on the
returned questionnaires.
Statistical methods
Frequencies and percentages are used to display re-
sponses to individual questions, with bubble plots illus-
trating responses to linked questions. Box and Whisker
plots are used to display respondents’ acceptable levels
of 4-year DFS within the various scenarios, and random
effects modelling was applied. Results were presented
graphically as the mean respondent’s levels (and 95%
confidence intervals (CI)) over the different scenarios, as
predicted by the model.
Results
Respondents
In July 2016, the questionnaire was circulated to the 152
randomising hospitals for the Persephone trial. By De-
cember 2016, responses had been received from 51 clini-
cians at 40 of the hospitals.
Perceptions of 4-year DFS
When asked about their perceptions of 4-year DFS with
6-months trastuzumab, 60% of responders (30 of the 50
who responded to this question), believed it to be 85%,
with responses ranging between 80 and 88% (Fig. 1a).
When asked what the lowest level of 4-year DFS was
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that they would be comfortable with in order to change
their current practice to 6-months trastuzumab, the
most common response was 83% (19/49 responders
(39%), range 75–85%, Fig. 1b). Only 3 responders (6% of
the 49 who answered both questions) quoted expecta-
tions of 4-year DFS lower than their stated lowest ac-
ceptable level and thus do not expect to change their
clinical practice (Fig. 1c). The remaining 94% have a
prior belief that 6-months trastuzumab delivers appro-
priate levels of DFS and are waiting for the evidence to
be strong enough to be able to change their clinical
practice.
Perceptions of the relative efficacy of 6 and 12 months of
trastuzumab in various subsets
Eight subsets of breast cancer were listed and respon-
dents were asked to indicate for each one whether they
thought that, in terms of disease-free-survival, 6 months
trastuzumab was an inferior treatment, an equivalent
treatment or a superior treatment when compared to
12 months trastuzumab. The most common opinion
expressed was of equivalent efficacy between 6 and
12 months of trastuzumab (Fig. 2), with between 58%
and 84% of responders choosing this option across the
different subsets. The subsets that gained the highest
ratings for inferior efficacy with 6-months were the no
anthracycline or taxane group (42%, 21/50), the ER
negative group (41%, 21/51) and the sequential trastuzu-
mab group (35%, 18/51). Four responders (8% of 51)
rated 6-months of trastuzumab superior in efficacy to
12-months in the taxane and anthracycline sub-group.
Additional subsets proposed by responders with per-
ceived equivalent efficacy between 6 and 12 months tras-
tuzumab were lower grade (n = 1), small low grade (n =
1) and T1 N0 ER + ve HER2 + ve (n = 1). Additional sub-
groups proposed by responders in which 6-months tras-
tuzumab was perceived to have inferior efficacy to 12-
months were (heavily) node positives (n = 4 respondents)
, patients in the neo-adjuvant setting (n = 1), patients re-
ceiving no chemotherapy (n = 1), higher grade (n = 1)
and large high grade tumours (n = 1). One respondent
perceived superior efficacy with 6-months trastuzumab
in small node negatives.
Perceived rates of cardiotoxicity
When asked about their opinions on the percentage of
patients who would suffer clinically relevant congestive
heart failure (CHF) whilst receiving 12-months trastuzu-
mab, responses ranged from 0.5% to 10% (median (inter-
Fig. 1 6-months trastuzumab: Opinions on 4-year DFS. a Expected
4-year DFS of patients receiving 6-months trastuzumab. b Lowest
acceptable 4-year DFS to change practice to 6-months trastuzumab.
c Expected vs lowest acceptable levels
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quartile-range (IQR)) 2% (1–4%)) (Fig. 3a). Opinions of
such figures for patients receiving 6-months trastuzu-
mab ranged from 0% to 10% (median (IQR) 1% (1–2%)).
A third of responders (16/50 (32%)) perceived exactly
equal rates of CHF across the two treatment durations.
The remaining 34 responders perceived a reduction with
6-months trastuzumab, from 25% fewer to 100% fewer
patients (i.e. no patients suffering CHF with 6-months
trastuzumab).
Respondents’ perceptions of the percentage of patients
reporting abnormal LVEF results during treatment were
slightly higher. Responses for 12-months trastuzumab pa-
tients ranged from 2% to 15% (median (IQR) 5% (4–8%))
and, for patients receiving 6-months trastuzumab, ranging
from 0% to 15% (median (IQR) 3.5% (2–5%)) (Fig. 3b).
Only 14% of responders (7/50) perceived equal rates of ab-
normal LVEF reporting. The remaining 43 responders per-
ceive a reduction with 6-months trastuzumab, from 10%
fewer to 100% fewer (i.e. no patients reporting abnormal
LVEF results with 6-months trastuzumab).
Acceptable trade-offs of DFS and cardiotoxicity
Respondents were asked to assume that 4-year DFS with
12-months trastuzumab was 85%. They were then pre-
sented with various hypothetical absolute increases in car-
diotoxicity with 12-months trastuzumab when compared
to 6-months and asked, for each proposed increased level,
what 4-year DFS with 6-months trastuzumab they would
find acceptable to achieve the lower level of cardiotoxicity.
As the rates of patients reporting cardiotoxicity increased
with 12-months trastuzumab, from 1%, 2%, 3%, 5%, 7%
and 10% more, respondents reported median (IQR) ac-
ceptable levels of 4-year DFS with 6-months trastuzumab
dropping to 84% (83–85), 83% (83–84), 83% (82–83), 80.
5% (80–83), 80% (79–82) and to 80% (75–80) respectively
(Fig. 4).
As the hypothetical gap between the levels of patients
suffering cardiotoxicity with 12 and 6-months trastuzu-
mab widened, respondents accepted significantly lower
levels of 4-year DFS with 6-months trastuzumab (Fig. 5,
p < 0.0001).
Additional comments
In the final free text section of the questionnaire, where
respondents could write about their views on any aspect
of the comparison between different durations of trastu-
zumab, comments were made on 4-year DFS (‘I do not
want to accept DFS <80%; hence I have not responded to
x +7% and x+10% (above)’. Comments also focused on
cardiotoxicity (‘Many believe 6 monthly Trastuzumab is
(sufficient with) low cardiotoxicity’ and ‘I am of the opin-
ion that most of the cardiotoxicity we see is reversible
and not permanent’). Respondents stressed how import-
ant the trade-off is between cardiotoxicity and DFS, and
highlighted that it was a shared decision making process
(‘I have put my views but shared decision making re-
quires the patient's views. Some will rate fear of recur-
rence very highly and not be so concerned about the risk
of cardiac toxicity. Some will take the reverse view’). One
respondent emphasised their view that to change clinical
practice the results would have to be near to equivalent
(‘the absolute benefit of Herceptin needs to be near
equivalent with 6 months regimen compared with the 12
months for it to be acceptable to patients and clinicians’).
Discussion
Sixty percent of the responders to our questionnaire be-
lieve that 6-months trastuzumab treatment will afford
Fig. 2 Opinions of the relative efficacy of 6 compared to 12 months of trastuzumab in various subsets
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exactly the same 4-year DFS as that expected with 12-
months trastuzumab treatment (85% 4-year DFS). Al-
most all (94% of responders) expect to change their clin-
ical practice to 6-months trastuzumab if 4-year DFS
levels with 6-months trastuzumab are shown to be what
they are expecting. The common consensus is that,
across all the subsets of breast cancer, and types and se-
quence of chemotherapy, 6 and 12 months trastuzumab
have equivalent efficacy. A minority of respondents be-
lieved that there might be some groups who would po-
tentially still require 12 months trastuzumab. These
included patients in the non-anthracycline or non-
taxane groups, the group who received sequential trastu-
zumab after chemotherapy, and ER negative patients.
The consensus prior belief therefore (including the
minority respondents) is that if both anthracyclines and
taxanes are given as chemotherapy, and concomitant
trastuzumab is used (with the taxane component) that
6 months is equivalent / acceptably non-inferior to
12 months. In 2017, in the UK the majority of patients
receiving adjuvant trastuzumab in this setting do already
receive concomitant treatment, and anthracycline / tax-
ane chemotherapy.
Since the trastuzumab duration questionnaire was
circulated in July 2016 the results of a cardiology ana-
lysis has been published on 2500 Persephone patients
[16] showing reported rates of clinical cardiac dysfunc-
tion as 12% and 9% for 12-month and 6-month trastu-
zumab patients respectively. Similarly, 12% and 9% of
patients respectively reported low LVEFs. Responders
to this questionnaire generally believed that cardiotoxi-
city rates would be lower than those we have reported,
some even believing there would be no cardiotoxicity at
all with 6-months trastuzumab. Now that these higher
rates of cardiotoxicity have been shown, with both 6
and 12-months trastuzumab, there will be heightened
interest in the DFS results of the Persephone trial (due
Fig. 5 Random Effects modelling predicted lines and 95% CIs
Fig. 3 Perceived rates of patients reporting cardiotoxicity during
treatment. a CHF: Clinically relevant congestive heart failure.
b Abnormal LVEF: LVEF< 50% or an ECHO/MUGA classed as
‘abnormal’ by a cardiologist
Fig. 4 Acceptable 4-year DFS with 6-months trastuzumab to avoid
hypothetical increased levels of cardiotoxicity
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mid-2018) from the perspective of balancing efficacy
and cardiotoxicity.
The definitions of significant cardiotoxicity and even
reduction in LVEF have varied considerably in the differ-
ent trial reports. This could be one reason why re-
sponders prior beliefs of the rates of cardiotoxicity were
lower than those actually reported from the Persephone
trial. In the trastuzumab duration questionnaire, clinical
cardiac dysfunction was defined as any symptoms or
signs of congestive heart failure or the patient receiving
any new or altered medication for cardiac disease. An
abnormal LVEF was defined as LVEF < 50% or an
ECHO/MUGA classed as ‘abnormal’ by a cardiologist.
The HERA trial reported significant LVEF drops, defined
as a decline in LVEF of > = 10% from baseline to < 50%
[12]. In Persephone, such significant LVEF drops were
reported by 9% of 12-month patients and 7% of 6-month
patients [16]. Persephone also reported the percentage
of patients with an LVEF< 50% after a baseline of > =
59% (6% of 12-month patients and 5% of 6-month pa-
tients [16]. Regardless of the definition used, in general
the responders to our questionnaire underestimated the
proportion of patients suffering cardiotoxicity with the
two durations.
The trade-offs between cardiotoxicity and DFS are
considerable. With proven absolute differences of 3%
between cardiotoxicity levels with 12 and 6-months
trastuzumab (both in terms of rates of patients report-
ing clinical cardiac dysfunction and in terms of patients
reporting low LVEFs) [16] 83% 4-year DFS with 6-
months trastuzumab is seen to be deemed acceptable
by responders to this questionnaire (Fig. 4). This con-
stitutes an absolute drop of 2% from the expected 85%
4-year DFS with 12-months trastuzumab. This is im-
portant information on prior clinical beliefs to help
define endpoints in a planned meta-analysis of trastu-
zumab duration trials.
All endeavours to maximise the response rate in this
study were undertaken, including multiple circulations
of the survey to sites and multiple email reminders.
However, it must be acknowledged that the small sam-
ple size within this study (51 respondents) remains a
limiting factor in terms of the generalisability of the
findings. In addition, the survey only included sites par-
ticipating in the Persephone trial and this could also be
viewed as a limitation since clinicians recruiting pa-
tients to the trial would continue to be in ‘clinical equi-
poise’ with regards to the six versus twelve month
duration question. However, this survey was under-
taken under the ethical approval obtained for the Per-
sephone trial and thus the set of 152 recruiting sites
defined the pool of participants available to us. Results
from this survey were presented at the NCRI Cancer
conference 2017 [17].
Conclusion
There was an expectation from 94% (46/49) of re-
sponders that they would change their clinical practice
to 6-months trastuzumab if their prior beliefs with
regards to 4 years DFS were confirmed by the results of
the Persephone trial. The most commonly held prior be-
lief was that the lowest acceptable 4-year DFS was 83%
with 6-months trastuzumab compared to 85% 4-year
DFS for 12 months. Significantly lower levels of 4-year
DFS with 6-months trastuzumab were deemed accept-
able with hypothesised increases in cardiotoxicity. An in-
dividual patient meta-analysis of the duration trials
would give greater precision to estimates of the differ-
ences in efficacy and toxicity, and adequate statistical
power to establish a 2% level of non-inferiority for 6-
months adjuvant trastuzumab.
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that was completed by the oncologists. (PDF 476 kb)
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